Date: 2016-08-23
Type of information: Private placement
Company: OncoMed Pharmaceuticals (USA - CA)
Investors:
Amount: $59.2 million
Funding type: private placement
Planned used:
Others: * On August 23, 2016, OncoMed Pharmaceuticals announced the completion of its previously announced underwritten public offering of 6,325,000 shares of its common stock at a public offering price of $10.00 per share, which includes the exercise in full of the underwriters' right to purchase up to an additional 825,000 shares of common stock. All shares in the offering were sold by OncoMed, with gross proceeds to OncoMed of approximately $63.3 million and net proceeds of approximately $59.2 million, after deducting underwriting discounts and commissions and estimated offering expenses.
Leerink Partners LLC acted as sole book-running manager for the offering. Wells Fargo Securities, LLC and JMP Securities LLC acted as co-managers.
Therapeutic area: Cancer - Oncology
